This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of
E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD)
chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the treatment of
relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are at a higher risk for
failure of CAR-T therapy.
E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the
catalytic domains of diphtheria toxin. This trial is designed to augment lymphodepletion
prior to CAR-T cells by administration of a targeted immunotoxin against CD25-expressing
T-cells. CD25 is expressed at high levels on Tregs but also on activated effector T cells.
The use of the CAR-T cell product and associated apheresis and LD chemotherapy is considered
standard of care (SOC).
Diffuse Large B-Cell Lymphoma,
diffuse large cell lymphoma,
diffuse large b cell lymphoma,
High-grade B-cell Lymphoma,
DLBCL Arising From Follicular Lymphoma,
High-grade B-cell Lymphoma
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.